Novel mechanisms underlying rapid-acting antidepressants: ketamine-like compounds, neurosteroid GABAkines, and psychedelics.
Drug discovery today – June 01, 2025
Source: PubMed
Summary
Breakthrough depression treatments now work in hours instead of weeks. Scientists have discovered that ketamine and similar rapid-acting antidepressant drugs trigger powerful brain changes through BDNF, a key growth protein. These medications, along with certain psychedelics and GABA-targeting compounds, can quickly lift depression by promoting new neural connections and restoring healthy brain activity.
Abstract
The discovery of the rapid antidepressant action of ketamine accelerated the identification of new molecules that are associated with fast and prolonged relief of depressive symptoms. As a result, a new group of antidepressants have emerged, some of them already approved for clinical use, classified as rapid-acting antidepressant drugs (RAADs). Potentiation of brain-derived neurotrophic factor (BDNF) or activation of the GABAA receptors are the main mechanisms behind the notable properties of RAADs, a mainstream topic in the field of pharmacology and drug discovery that deserves an updated review.